enGene Holdings Inc. (NASDAQ: ENGN) (NASDAQ: ENGNW), a Canada-based clinical-stage genetic medicines company, announced on Wednesday that it has named Ryan Daws as its new chief financial officer and head of Business Development.

Daws has around 25 years of life sciences-focused operational and deal-making experience. He has served as chief financial officer and head of Business Development at Obsidian Therapeutics, Inc, managing director with the Healthcare Investment Banking Group at Robert W Baird & Co., Inc, chief financial officer and head of Business Development at Concert Pharmaceuticals, Inc. He has spent around 15 years originating and executing equity and mergers and acquisitions transactions in the life sciences sector, first at Cowen and Company, LLC and then Stifel, Nicolaus & Co, Inc.

Jason D Hanson, enGene chief executive officer, said, 'I am delighted to welcome Ryan to enGene at a critical time in our growth, as we move forward as a public company and work to advance our ongoing pivotal-stage EG-70 clinical study in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Ryan's significant experience across multiple areas of financial, business development and operational management in the pharmaceutical industry, as well as healthcare investment banking, complements our leadership team. We look forward to working with Ryan to continue to serve our shareholders, clinicians, and ultimately patients, in pursuit of our longstanding goal of mainstreaming gene therapy and bringing our genetic medicines to community clinics across the globe.'